Objective: Patients with Graves disease (GD) tend to gain weight after treatment, but it remains unknown if weight gain is associated with increase in visceral and/or subcutaneous fat area (SFA,VFA).
Introduction
Graves disease (GD) is the most common endocrine disease that causes hyperthyroidism. GD is caused by autoantibodies that stimulate and activate the thyrotropin receptor, resulting in an excessive production of thyroid hormone [1] . One of the important symptoms of individuals with GD is weight loss, which is caused by accelerated catabolism despite of excessive caloric intake. GD can be treated with antithyroid drugs, radioactive iodine, or surgery. Patients with GD are known to gain body weight after their thyroid function is improved. Moretto et al. showed that the body weight (BW) and body mass index (BMI) increased significantly in patients with GD after treatment with antithyroid drugs: the percentage of patients with a BMI >25 kg/m2 increased from 33.3% to 62.0% after treatment [2] . Similarly, weight gain was observed in patients with GD treated for 6 months, irrespective of their treatment [3] .
It is known that weight gain is in general associated with an increase in visceral adipose tissue. Many studies have shown that visceral fat is an important risk factor that contributes to diabetes mellitus and cardiovascular diseases [4] [5] [6] . Individuals with a visceral fat area (VFA) >100 cm2 have shown high serum levels of triglycerides (TG), high blood pressure, and a high-glucose profile on glucose tolerance tests [7] . In addition, increased VFA has been shown to increase the mortality risk associated with cardiovascular disease [8] .
Patients with GD are known to be at higher risk of developing cardiovascular diseases and diabetes mellitus even after the treatment of their GD [9] . Individuals with GD have also been shown to be at high risk of hospitalization due to cardiovascular disease, and this risk remains unchanged for >10 years after the improvement their hyperthyroidism by a thyroidectomy [10] . We have thus speculated that weight gain may be associated with an increase in visceral or subcutaneous fat area in patients with Graves disease and that this association is relevant given the risk of fatty liver, type 2 diabetes, and eventually cardiovascular disease that comes with increase in visceral fat. We herein examined the VFA and subcutaneous fat area (SFA) of patients with GD from before to after their treatment.
Patients and Methods
Thirty patients with GD that was newly diagnosed during the period from May 2014 to November 2017 at Nagasaki University Hospital, Nagasaki, Japan were enrolled. The diagnosis of GD was based on the presence of thyrotoxicosis accompanied by positive thyroid-stimulating hormone (TSH) receptor antibodies with or without goiter. All of the patients were treated with antithyroid drugs at our hospital. Clinical parameters including physical measurements and biochemical and hormonal data at the baseline were collected from each patient's medical records. The dose adjustment of antithyroid drugs was made by each patient's physician. The SFA and VFA of each patient were measured before his or her treatment with antithyroid drugs every 3 months after the initiation of treatment with the use of a DualScan® (HDS-2000, Omron, Kyoto). The DualScan® measures the VFA and SFA at the level of the navel by conducting a dual bioelectrical impedance analysis without radiation exposure. The VFA and SFA measured by this method have been shown highly correlated with the corresponding values obtained by computed tomography [11] . Our patients were advised to skip breakfast on the days of their SFA and VFA measurements. This study was approved by our hospital's ethics committee (approval no. 14012741) and carried out in accordance with the Declaration of Helsinki. Written informed consent to have their data analyzed in this study and published was obtained from each patient.
Thirty patients with newly diagnosed GD were enrolled in this study. For the analysis, we identified 25 of these patients whose data at both the baseline and 6 months were available. We divided these 25 patients into two groups, upper half and lower half, based on at the median value of the percent increases in their VFA and SFA values at 6 months after treatment. We compared the clinical parameters at the baseline between the two groups to evaluate factors that influence the increase in the VFA and/or SFA after treatment for Graves' disease.
Statistical analysis
The Wilcoxon signed rank test was used to test the differences in the rates of change in the patients' body weight (BW), VFA, and SFA from before to after the start of their treatment for GD. The patients' baseline characteristics are summarized as frequencies and percentages for categorical data and the median plus interquartile range (IQR) for continuous data. We evaluated the correlation of the percent change between fat area and BW at 6 months of treatment by using determining the Spearman rank correlation coefficient. Using the Spearman rank correlation coefficient, we also evaluated the correlation between the percent change from baseline to 6 months in thyroid hormone concentrations and the present change in each of BW, SFA, and VFA. We divided the patients into two groups based on the median increase in the rate of VFA or SFA at 6 months of treatment. The differences between the groups were assessed by Fisher's exact test for categorical data and Wilcoxon's rank sum test for continuous data. To adjust the analyses for confounders, we included potential confounding variables that contributed to the outcome with a p-value <0.2 in simple logistic regression analyses and those with p-values 0.05 in a multiple logistic regression analysis.
Because there is a significantly positive correlation between the change rates of BW and the SFA, we chose the SFA to avoid multicollinearity. Similarly, because thyroid hormones influence the levels of alkaline phosphatase (ALP) and TG, we included free thyroxine (T4) and no other significant confounding variables. All statistical analyses were performed using JMP Pro ver. 13 (SAS, Cary, NC, USA). P-values <0.05 were considered significant.
Results
The VFA and SFA values determined both at the baseline and at 6 months after the initiation of treatment were available in 25 patients (3 males and 22 females; median age 33.0 years). The characteristics of the 25 patients are shown in Table 1 . The changes in the patients' body weight, VFA, and SFA over the 6 months of treatment are illustrated in Figure   1 . The body weights of all 25 patients increased significantly from 54.3 ± 10.3 kg to 58.0 ± 11.2 kg (mean ± SD) over the 6 months of treatment. There was a positive correlation between the percent change in body weight and the percent change in the SFA (ρ=0.591, p=0.002), but not with the percent change in the VFA (ρ=0.078, p=0.712). There was no correlation between the VFA and SFA values determined before and after treatment (ρ=-0.189, p=0.365).
We then divided these 25 patients into two groups based on the median of the change rate of the VFA (Table 2) or SFA (Table 3 ) over the 6 months of treatment. The results of our analyses demonstrated that the patients with a greater increase in the VFA had significantly lower VFA values at the baseline (33.9 [22.7-47.5] cm2) compared to the patients with smaller increases (54.5 [45.2-64.0] cm2) (p=0.011). There were no significant correlations between other physical and biochemical/hormonal parameters between the two groups.
We also observed that a greater increase in the SFA was associated with lower systolic blood pressure and lower ALP at the baseline. We investigated whether there was a significant difference in thyroid hormone levels at 6 months between the two patient groups:
there was no significant between-group difference in thyroid hormone concentrations or in the changes in these concentrations over the 6 months of treatment. We also studied correlation of the percent change of thyroid hormones with the percent changes in body weight, SFA and VFA, but there were no significant correlations.
We then performed a univariate logistic regression analysis using six parameters (the baseline values of SFA, free T3, free T4, thyrotropin receptor antibodies, ALP, and TG) to determine whether any of these parameters are associated with an increase in the SFA at 6 months of treatment for GD. The analysis revealed that thyroid hormones and ALP were associated with the percent increase in the SFA (Table 4 ). A multivariate logistic analysis was performed to predict the increase in the SFA by using either ALP and free T3 (Table 5A) or ALP and free T4 (Table 5B ) as explanatory variables. The results showed that the baseline value of free T3 was negatively associated with the increase in the SFA after 6 months of treatment: OR 0.83 (95%CI: 0.61-1.00), p=0.043.
Discussion
It has been very recently reported that the proportion of hyperthyroidism patients whose BMI were more than 30 kg/m2 was larger after treatment indicating that treatment for hyperthyroidism was associated with increased risks of becoming obese [12] . In studies focused on only GD patients, an increase in body weight over 6 months of treatment for GD has been reported in both adults and children [13, 14] . Most of the body weight gain after treatment was related to an increase in lean mass as determined by the body composition in nine patients with thyrotoxicosis [15] . Non-significant increases in the fat and mineral content of patients with GD after treatment were also reported [15] . The results of our present investigation demonstrated that both the VFA and SFA values of the 25 patients with GD were significantly increased at 6 months of treatment. The increase in the SFA, but not in the increase in the VFA, seemed to contribute to the gain in body weight of our patients with GD.
It is well recognized that excessive thyroid hormone increases the basal metabolic rate in hyperthyroidism [16] , and patients with GD are known to develop weight loss. This weight loss can be expected to be due to a chronic excessive energy expenditure which cannot be compensated for by an enhanced caloric intake. The question of what happens to an individual's energy balance after his or her thyroid function is improved by medical treatment remains to be answered. It is also well known that overt thyroid dysfunction affects the resting energy expenditure [17] . Lönn et al. reported an approx. 40% reduction in their patients' basal metabolic rate after 12 months of medical treatment for GD compared to the values obtained at the diagnosis [18] . Patients with GD thus gain weight if their caloric intakes remain excessive after the improvement of their thyroid function.
It has been reported that excessive body weight may influence thyroid hormone levels within the euthyroid range [19] . Obese individuals are known to have high free T3 levels, and high free T3 might contribute to fat combustion [20] . High free T3 converts white fat cells to brown fat cells and increases thermogenesis [21] . Thus, the fat is expected to burn and accumulate less in thyrotoxicosis. We observed that free T3 at the presentation of GD was lower in our patients with a greater accumulation of SFA than in that in the patients with smaller SFA accumulations. There was no significant difference in our patients' serum levels of free T3 after 6 months of treatment, and there was no significant difference between the two patient groups in the change in free T3 values over the 6 months of treatment. It thus seems to be the baseline free T3 level that affects the fat area change after treatment for GD.
Since T3 levels are known to influence the conversion from white fat cells to brown fat cells [21] , GD patients with high T3 might have lesser amounts of white fat cells at the baseline, and this might be related to the lower weight gain and less accumulation of subcutaneous fat.
Hyperthyroidism is known to cause various cardiovascular complications and to increase the mortality and risk of cardiovascular diseases [22] . This is caused by excess triiodothyronine's effects on the heart and the cardiovascular system and a reduction in the systemic vascular resistance and increase in the heart rate at rest, the left ventricular contractility, the blood volume, and the cardiac output [23] . T3 excess also causes atrial fibrillation, arterial hypertension, thyrotoxic cardiomyopathy, and eventually congestive heart failure [24] . In addition, patients with GD have been reported to be at a higher risk of mortality, due mainly to a thromboembolism caused by atrial fibrillation [25] , and as noted above, patients with GD have higher risks of cardiovascular diseases and diabetes mellitus for >10 years after the treatment of their hyperthyroidism [9, 10] . It remains unclear why the risks of cardiovascular disease and diabetes continue to be higher even after hyperthyroidism improves in GD patients.
In the present study, we focused on the changes in the patients' body fat content induced by treatment as a potential cause of metabolic and cardiovascular disorder in patients with GD. Our results suggest that the body weight gain after the treatment of GD was caused mainly by an increase in subcutaneous fat but not by an increase in visceral fat.
This might have been due to our cohort being predominantly young females who tend to increase their subcutaneous fat mass associated with weight gain [26] . Visceral fat is well known to be associated with the risks of metabolic syndrome and cardiovascular disease.
Fox et al. showed that both visceral fat and subcutaneous fat were correlated with metabolic risk factors, and they stated that it was visceral fat (and not subcutaneous fat) that was strongly associated with metabolic risks such as blood pressure, fasting plasma glucose, diabetes mellitus, and metabolic syndrome [27] . Another study showed that an increase in subcutaneous fat contributed to decreases in metabolic and cardiovascular risks such as diabetes or dyslipidemia [28] . Jung et al. reported that subcutaneous fat was inversely associated with carotid atherosclerosis in patients with type 2 diabetes mellitus [29] . Thus, there is no consistent conclusion regarding the association of subcutaneous fat with the risks for metabolic and cardiovascular disorders.
There are several study limitations to address. The sample size was small (n=25). The patients were relatively young and the follow-up term was short for considering cardiovascular risk. There is clear bias in race and gender; most of the patients were Japanese females.
In conclusion, within 6 months of treatment for GD, normalizing hyperthyroidism caused gains in the patients' body weight, visceral fat (VFA) and subcutaneous fat (SFA).
The increase in subcutaneous fat seemed to contribute to the gain in body weight. A lower free T3 level before treatment was associated with an increase in the SFA after treatment. (kg) (cm 2 ) (cm 2 ) BW SFA VFA p<0.001 p=0.004 p=0.008
(months)
Wilcoxon's signed rank test was used to test difference in the BW, VFA, and SFA from baseline to 6 months of GD treatment. The differences between groups were assessed by Fisher's exact test for categorical data and
Wilcoxon's rank sum test for continuous data. The differences between groups were assessed by Fisher's exact test for categorical data and Wilcoxon's rank sum test for continuous data. subcutaneous fat area, TRAb; TSH receptor antibody.
We included potential confounding variables that were likely to contribute to increase in subcutaneous fat area in Table 3 (p < 0.2) in this analysis. Odds ratio, 95% confidence intervals and p values of each characteristics were evaluated with unadjusted logistic regression models. Abbreviations: OR; odds ratio, CI; confidence interval.
We included confounding variables that were significant in unadjusted logistic regression analysis, namely thyroid hormones and ALP, in adjusted logistic regression analysis. Since free T3 correlate with free T4, we analyzed separately to avoid multicollinearity.
